Schrezenmeier H, Kulasekararaj A, Mitchell L, de Latour RP, et al. Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. Ann Hematol 2024;103:5-15.
PMID: 37804344